Keywords: elan, 3rd-quarter, loss, widens, irish, biotechnology, firm

Elan's 3rd-quarter 2006 loss widens 74%

Article | 06 November 2006

Irish biotechnology firm Elan saw widening losses in the third quarter of 2006 after its troubled mutiple sclerosis drug Tysabri (natalizumab; ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Drugs

Natalizumab

Tysabri

Prialt

Ziconotide

Zonegran

Go to drug listing